Health Care [ 4/12 ] | Biotechnology [ 22/74 ]
NASDAQ | Common Stock
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage.
It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers.
Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.63 Increased by +1.56% | -0.35 Decreased by -80.00% |
| Oct 31, 24 | 0.38 Increased by +170.37% | -0.25 Increased by +249.31% |
| Jul 30, 24 | -0.05 Increased by +91.80% | -0.75 Increased by +93.33% |
| May 6, 24 | -0.72 Decreased by -22.03% | -0.66 Decreased by -9.09% |
| Feb 26, 24 | -0.64 Decreased by -14.29% | -0.58 Decreased by -10.34% |
| Nov 6, 23 | -0.54 Decreased by -1.89% | -0.60 Increased by +10.00% |
| Aug 7, 23 | -0.61 Decreased by -1.67% | -0.61 |
| May 1, 23 | -0.59 Decreased by -22.92% | -0.59 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 29.21 M Increased by +5.12 K% | -65.71 M Decreased by -20.55% | Decreased by -224.99% Increased by +97.69% |
| Sep 30, 24 | 93.76 M Increased by +N/A% | 37.04 M Increased by +180.25% | Increased by +39.50% Decreased by N/A% |
| Jun 30, 24 | 8.19 M Increased by +N/A% | -4.41 M Increased by +90.39% | Decreased by -53.80% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -62.41 M Decreased by -76.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 560.00 K Increased by +N/A% | -54.51 M Decreased by -56.57% | Decreased by -9.73 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -46.15 M Decreased by -35.75% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -45.86 M Decreased by -25.55% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -35.38 M Decreased by -27.51% | Decreased by N/A% Decreased by N/A% |